![]() ![]() Were assigned to the adjuvant-CapOx, 340 (33%) patients to the adjuvant-SOX group,Īnd 337 (33%) patients to the perioperative-SOX group. Were included in the modified intention-to-treat population, of whom 345 (34%) patients This study is registered with, NCT01534546. Least one dose of the assigned treatment. Safety analysis were done in patients who received at Survival to assess the superiority of perioperative-SOX compared with adjuvant-SOXĪnd the non-inferiority (hazard ratio non-inferiority margin of 1♳3) of adjuvant-SOXĬompared with adjuvant-CapOx. Primary endpoint, assessed in the modified intention-to-treat population, 3-year disease-free ESF JIREN MODEL PLUSSOX (intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day plus oral S-1 40–60 mg twice a day for three cycles preoperativelyĪnd five cycles postoperatively followed by three cycles of S-1 monotherapy). System, stratified by participating centres and Lauren classification, to receiveĪdjuvant CapOx (eight postoperative cycles of intravenous oxaliplatin 130 mg/m 2 on day one of each 21 day cycle plus oral capecitabine 1000 mg/m 2 twice a day), adjuvant SOX (eight postoperative cycles of intravenous oxaliplatinġ30 mg/m 2 on day one of each 21 day cycle plus oral S-1 40–60 mg twice a day), or perioperative Undergoing D2 gastrectomy were randomly assigned (1:1:1) via an interactive web response Junction adenocarcinoma, with Karnofsky performance score of 70 or more. Years or older with historically confirmed cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal We recruited antitumour treatment-naive patients aged 18 We did this open-label, phase 3, superiority and non-inferiority, randomised trialĪt 27 hospitals in China. ![]() The Lancet Regional Health – Western Pacific.The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |